MICHAEL GRAZIANO, PhD
IQ Board of Directors Member (2021-Present)
IQ Preclinical Safety Leadership Group (now DruSafe) Chair (2011)
IQ DruSafe Member (2012-Present)
Associate Vice President, Preclinical Development, Organon LLC
PhD, Toxicology, University of Kentucky
HOW DID YOU FIRST GET INVOLVED IN THE IQ CONSORTIUM?
I was part of a small group of individuals that started IQ back in 2010. R&D subject matter experts needed a new forum to discuss common pharma industry issues and share ideas in a noncompetitive manner that would benefit all participating members. While the founders of IQ certainly believed in its value and mission, I don’t think any of us predicted how large and successful IQ would be 10 years later. Congratulations to IQ and Faegre Drinker and thank you to everyone who was part of this journey!
WHAT FACTORS HELPED SHAPE THE GROWTH OF IQ?
IQ is an organization that gets things done. It is action oriented and very proactive. It relies on the collective energy, enthusiasm, and expertise of all it as members to identify, discuss, and address issues common to the industry. Many companies have joined IQ after recognizing the enormous impact IQ has on the scientific and regulatory environment. It is not a stretch to say that IQ is now recognized by the FDA as the pre-eminent scientific and technical organization that represents the US pharmaceutical industry.
WHAT ARE THE BENEFITS OF MEMBERSHIP IN THE IQ CONSORTIUM?
By raising issues and sharing ideas in the pre-competitive space, membership in IQ promotes a growth mindset that enables scientific and leadership development. It can also lead to the adoption of more efficient work processes and more robust scientific strategies. In addition, member companies may also get broad support and access to shared LG resources to address topics of mutual interest for which they may lack internal resources and/or scientific expertise to pursue on their own.